Ani Pharmaceuticals (ANIP) Intangibles (2012 - 2026)

Ani Pharmaceuticals has disclosed Intangibles across 15 years of filings, most recently posting $467.2 million for Q1 2026.

• Intangibles for Q1 2026 came in at $467.2 million, down 13.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $467.2 million (down 13.25% YoY), and the FY2025 annual result was $479.5 million, down 11.5% from the prior year.
• Intangibles came in at $467.2 million for Q1 2026 at Ani Pharmaceuticals, down from $479.5 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $569.8 million in Q3 2024 to a low of $4.3 million in Q2 2023.
• The 5-year median for Intangibles is $269.6 million (2022), against an average of $322.0 million.
• Across the five-year window, Intangibles tumbled 98.41% in 2023 and jumped 4157.63% in 2024, its largest moves.
• Ani Pharmaceuticals' Intangibles stood at $251.6 million in 2022, then dropped by 16.94% to $209.0 million in 2023, then jumped by 159.24% to $541.8 million in 2024, then declined by 11.5% to $479.5 million in 2025, then retreated by 2.58% to $467.2 million in 2026.
• The last three Intangibles figures came in at $467.2 million (Q1 2026), $479.5 million (Q4 2025), and $499.8 million (Q3 2025), per Business Quant data.